Zacks Investment Research Downgrades China Biologic Products (NASDAQ:CBPO) to Sell

Share on StockTwits

Zacks Investment Research lowered shares of China Biologic Products (NASDAQ:CBPO) from a hold rating to a sell rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

CBPO has been the topic of a number of other reports. ValuEngine lowered shares of China Biologic Products from a buy rating to a hold rating in a report on Saturday, June 1st. BidaskClub raised shares of China Biologic Products from a hold rating to a buy rating in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. China Biologic Products presently has an average rating of Hold and a consensus target price of $78.00.

CBPO opened at $98.79 on Thursday. China Biologic Products has a fifty-two week low of $60.08 and a fifty-two week high of $105.50. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 5.90 and a beta of 1.26. The company’s 50 day moving average price is $95.12 and its two-hundred day moving average price is $91.11.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported $1.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.21. China Biologic Products had a net margin of 29.46% and a return on equity of 8.56%. The firm had revenue of $135.70 million for the quarter. During the same period in the previous year, the firm earned $1.17 earnings per share. The company’s revenue was up 12.7% compared to the same quarter last year. As a group, research analysts expect that China Biologic Products will post 3.29 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of CBPO. York Capital Management Global Advisors LLC grew its stake in shares of China Biologic Products by 13.9% during the 2nd quarter. York Capital Management Global Advisors LLC now owns 1,128,717 shares of the biopharmaceutical company’s stock valued at $107,567,000 after acquiring an additional 137,484 shares during the period. Jane Street Group LLC bought a new position in shares of China Biologic Products during the 2nd quarter valued at approximately $486,000. Point72 Asset Management L.P. bought a new position in shares of China Biologic Products during the 2nd quarter valued at approximately $6,477,000. Vanguard Group Inc. grew its stake in shares of China Biologic Products by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 950,421 shares of the biopharmaceutical company’s stock valued at $90,575,000 after acquiring an additional 29,178 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of China Biologic Products by 446.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,761 shares of the biopharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,439 shares during the period. 35.41% of the stock is currently owned by institutional investors.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Further Reading: What is the Quick Ratio?

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

M&T Bank  Cut to “Sell” at Zacks Investment Research
M&T Bank Cut to “Sell” at Zacks Investment Research
Bank of America Trims Masco  Target Price to $54.00
Bank of America Trims Masco Target Price to $54.00
Kinross Gold  Raised to “Buy” at ValuEngine
Kinross Gold Raised to “Buy” at ValuEngine
Capital Bank & Trust Co Makes New Investment in First Trust Intrmdt Drtn Prfrd & Incm Fd
Capital Bank & Trust Co Makes New Investment in First Trust Intrmdt Drtn Prfrd & Incm Fd
Restoration Hardware  PT Raised to $185.00
Restoration Hardware PT Raised to $185.00
Grupo Supervielle  Stock Rating Lowered by Bank of America
Grupo Supervielle Stock Rating Lowered by Bank of America


© 2006-2019 Ticker Report